These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
83 related items for PubMed ID: 8724529
1. Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Gunther R, Chelstrom LM, Wendorf HR, Schneider EA, Covalciuc K, Johnson B, Clementson D, Irvin JD, Myers DE, Uckun FM. Leuk Lymphoma; 1996 Jun; 22(1-2):61-70, follow.186, color plate II-V. PubMed ID: 8724529 [Abstract] [Full Text] [Related]
2. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys. Uckun FM, Yanishevski Y, Tumer N, Waurzyniak B, Messinger Y, Chelstrom LM, Lisowski EA, Ek O, Zeren T, Wendorf H, Langlie MC, Irvin JD, Myers DE, Fuller GB, Evans W, Gunther R. Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689 [Abstract] [Full Text] [Related]
3. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Jansen B, Kersey JH, Jaszcz WB, Gunther R, Nguyen DP, Chelstrom LM, Tuel-Ahlgren L, Uckun FM. Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881 [Abstract] [Full Text] [Related]
6. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Ek O, Gaynon P, Zeren T, Chelstrom LM, Myers DE, Uckun FM. Leuk Lymphoma; 1998 Sep; 31(1-2):143-9. PubMed ID: 9720724 [Abstract] [Full Text] [Related]
7. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. Myers DE, Yanishevski Y, Masson E, Irvin JD, Evans WE, Uckun FM. Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835 [Abstract] [Full Text] [Related]
8. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. Myers DE, Irvin JD, Smith RS, Kuebelbeck VM, Uckun FM. J Immunol Methods; 1991 Feb 15; 136(2):221-37. PubMed ID: 1705571 [Abstract] [Full Text] [Related]
9. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia. Ek O, Reaman GH, Crankshaw DL, Chelstrom LM, Myers DE, Uckun FM. Leuk Lymphoma; 1998 Feb 15; 28(5-6):509-14. PubMed ID: 9613980 [Abstract] [Full Text] [Related]
10. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM. Blood; 1995 May 01; 85(9):2537-45. PubMed ID: 7537120 [Abstract] [Full Text] [Related]
15. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside. Messinger Y, Yanishevski Y, Avramis VI, Ek O, Chelstrom LM, Gunther R, Myers DE, Irvin JD, Evans W, Uckun FM. Clin Cancer Res; 1996 Sep 15; 2(9):1533-42. PubMed ID: 9816330 [Abstract] [Full Text] [Related]
17. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Gunther R, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Uckun FM. Leukemia; 1993 Feb 15; 7(2):298-309. PubMed ID: 7678882 [Abstract] [Full Text] [Related]
18. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. Uckun FM, Gajl-Peczalska KJ, Kersey JH, Houston LL, Vallera DA. J Exp Med; 1986 Feb 01; 163(2):347-68. PubMed ID: 3511171 [Abstract] [Full Text] [Related]
19. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia. Messinger Y, Reaman GH, Ek O, Uckun FM. Leuk Lymphoma; 1999 Apr 01; 33(3-4):289-93. PubMed ID: 10221508 [Abstract] [Full Text] [Related]
20. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin. Jansen B, Uckun FM, Jaszcz WB, Kersey JH. Cancer Res; 1992 Jan 15; 52(2):406-12. PubMed ID: 1370213 [Abstract] [Full Text] [Related] Page: [Next] [New Search]